Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea Corporis

This clinical trial will compare three cream treatments for tinea corporis, also called ringworm of the body. It will include Egyptian adults aged 18 to 65 years whose skin infection is confirmed by examining a skin scraping under a microscope. The main questions are: * Does using lactoferrin cream with luliconazole cream clear the infection better than either cream alone? * What side effects occur with each treatment? * Does the infection return after treatment? Participants will be assigned by chance to one of three groups: * Lactoferrin 2% cream and luliconazole 1% cream. * Luliconazole 1% cream and a matching cream without lactoferrin. * Lactoferrin 2% cream and a matching cream without luliconazole. The matching creams contain no active study ingredient and help keep treatment assignments hidden. Participants and the researchers assessing their skin will not know which treatment each participant receives. Participants will apply their assigned creams twice daily for four weeks. They will attend study visits for skin examinations, symptom assessments, and monitoring for side effects. Skin scrapings will be examined to check whether the infection has cleared. Researchers will also assess changes in the size of the affected areas, itching, treatment satisfaction, and whether the infection returns.

Inclusion Criteria: * Male or female patients aged 18 to 65 years. * Clinical diagnosis of tinea corporis. * Confirmation of dermatophytosis by direct microscopic examination using a potassium hydroxide (KOH) preparation. * Willingness to participate and provide written informed consent. Exclusion Criteria: * Known hypersensitivity to lactoferrin, luliconazole, or any component of the study formulations. * Pregnancy or breastfeeding. * Use of systemic or topical antifungal therapy within 4 weeks before enrollment. * Use of systemic or topical corticosteroids within 4 weeks before enrollment. * Immunocompromised status. * Current treatment with immunosuppressive therapy. * Other dermatological conditions that may interfere with clinical assessment. * Severe systemic diseases that may affect study outcomes.